Analyst Price Targets — KMDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 21, 2026 1:24 pm | — | William Blair | $15.00 | $7.27 | StreetInsider | Benchmark Reiterates Buy Rating on Kamada Ltd. (KMDA) as $50M Sales Agreement Announced |
| March 11, 2026 3:01 pm | Annabel Samimy | Stifel Nicolaus | $11.00 | $8.55 | StreetInsider | Stifel Reiterates Buy Rating on Kamada Ltd. (KMDA) |
| December 9, 2025 11:11 am | — | H.C. Wainwright | $13.00 | $6.73 | TheFly | Kamada price target raised to $13 from $11 at H.C. Wainwright |
| November 13, 2024 4:05 pm | Annabel Samimy | Stifel Nicolaus | $20.00 | $6.03 | StreetInsider | Kamada Ltd. (KMDA) PT Raised to $20 at Stifel |
Latest News for KMDA
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KMDA.
U.S. House Trading
No House trades found for KMDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.